William Bauta - BioAffinity Technologies Senior Therapeutics
| BIAFW Stock | USD 0.75 0.15 25.00% |
Executive
William Bauta is Senior Therapeutics of bioAffinity Technologies Warrant
| Address | 22211 West Interstate 10, San Antonio, TX, United States, 78257 |
| Phone | 210 698 5334 |
| Web | https://www.bioaffinitytech.com |
BioAffinity Technologies Management Efficiency
The company has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5152) %, meaning that it generated substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.39 in 2024. Return On Capital Employed is likely to climb to -1.27 in 2024. At this time, BioAffinity Technologies' Non Current Assets Total are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 10 K in 2024.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Quinton McGeer | Barloworld Ltd ADR | 58 | |
| Dallas Coleman | bioAffinity Technologies, | N/A | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 |
BioAffinity Technologies Leadership Team
Elected by the shareholders, the BioAffinity Technologies' board of directors comprises two types of representatives: BioAffinity Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioAffinity. The board's role is to monitor BioAffinity Technologies' management team and ensure that shareholders' interests are well served. BioAffinity Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioAffinity Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Overton, Director Communications | ||
| Dallas Coleman, National Sales | ||
| William Bauta, Senior Therapeutics | ||
| Maria JD, President, Founder | ||
| Steven Girgenti, Founder Board | ||
| Xavier MS, VP Operations | ||
| Timothy JD, Secretary VP |
BioAffinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioAffinity Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) | ||||
| Net Income | (7.94 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.58 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.